Program
Esketamine
Also written as “Esketamine 84 mg”, “Esketamine 56 mg” and “AM-101”.
Its studies are mostly in Depressive Disorder, Treatment-Resistant · Depressive Disorder, Major · Tinnitus · Depression · Substance-Related Disorders, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 412 open or running | phase 4since Oct 21, 2020 | Jul 11, 2012 | Dec 27, 2028phase 3 · NCT07716098 |
| Celon Pharma | 30 open or running | phase 2since May 21, 2019 | Jan 8, 2018 | none ahead |
| Chengdu Brilliant Pharmaceutical | 10 open or running | phase 3since Sep 21, 2023 | Sep 21, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 30 studies since Jul 11, 2012.
- Jan 8, 2018Celon Pharma's first study: phase 1 study in Healthy VolunteersNew to Celon PharmaCelon Pharma · NCT03407872 · 63 enrolled · Poland
- Feb 9, 2018Phase 3 study in Depressive Disorder, Treatment-ResistantJohnson & Johnson · NCT03434041 · 252 enrolled · United States, China
- Feb 12, 2019Phase 3 study in Depressive Disorder, Treatment-ResistantJohnson & Johnson · NCT03852160
- May 21, 20192 phase 2 studiesCelon Pharma · NCT03965871, NCT03965858
- Feb 21, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04282746 · 17 enrolled · Belgium
- Apr 6, 2020Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT04338321 · 676 enrolled · Argentina, Austria, Belgium and more
- Jul 15, 2020Phase 3 study in DepressionJohnson & Johnson · NCT04476446 · 41 enrolled · Mexico
- Oct 21, 2020Phase 4 study in Depressive Disorder, Treatment-ResistantJohnson & Johnson · NCT04599855 · 477 enrolled · United States
- Apr 1, 2021Phase 4 study in Depressive Disorder, MajorJohnson & Johnson · NCT04829318 · 183 enrolled · Argentina, Belgium, Bulgaria and more
- Feb 25, 2022Phase 1 study in DepressionJohnson & Johnson · NCT05268497 · United States
- Sep 21, 2023Chengdu Brilliant Pharmaceutical's first study: phase 3 study in LaparoscopyNew to Chengdu Brilliant PharmaceuticalChengdu Brilliant Pharmaceutical · NCT06092684 · 358 enrolled · China
- Jun 27, 2025Phase 4 study in Depressive Disorder, Treatment-ResistantJohnson & Johnson · NCT07053345 · 47 enrolled · South Korea
- Nov 11, 2025Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT07227454 · 258 planned · United States, Brazil, Hungary and more
- Jul 15, 2026Phase 3 study in Depressive Disorder, Treatment-ResistantJohnson & Johnson · NCT07716098 · 348 planned · United States, China, Japan and more
Ahead
- Dec 27, 2028Primary completion: phase 3 study in Depressive Disorder, Treatment-ResistantJohnson & Johnson · NCT07716098
- Apr 9, 2031Primary completion: phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT07227454
TargetBeta
“Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Memantinerule | AbbVie | phase 4 | 29 |
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07716098Depressive Disorder, Treatment-Resistant · United States, China, Japan and more | 3 | Recruiting | Johnson & Johnson | Dec 27, 2028 | 348 |
| NCT07227454Depressive Disorder, Major · United States, Brazil, Hungary and more | 3 | Recruiting | Johnson & Johnson | Apr 9, 2031 | 258 |
| NCT07053345Depressive Disorder, Treatment-Resistant · South Korea | 4 | Completed | Johnson & Johnson | Jul 13, 2026 | 47 |
| NCT06092684Laparoscopy · China | 3 | Completed | Chengdu Brilliant Pharmaceutical | Mar 19, 2024 | 358 |
| NCT05268497Depression · United States | 1 | Withdrawn | Johnson & Johnson | Jun 7, 2023 | 0 |
| NCT04829318Depressive Disorder, Major · Argentina, Belgium, Bulgaria and more | 4 | Completed | Johnson & Johnson | Jul 22, 2024 | 183 |
| NCT04599855Depressive Disorder, Treatment-Resistant · United States | 4 | Completed | Johnson & Johnson | Jan 31, 2024 | 477 |
| NCT04476446Depression · Mexico | 3 | Completed | Johnson & Johnson | Jun 16, 2023 | 41 |
| NCT04338321Depressive Disorder, Major · Argentina, Austria, Belgium and more | 3 | Completed | Johnson & Johnson | Jan 20, 2022 | 676 |
| NCT04282746Healthy · Belgium | 1 | Completed | Johnson & Johnson | Aug 11, 2020 | 17 |
| NCT03965871Bipolar Disorder · Poland | 2 | Completed | Celon Pharma | Jan 3, 2021 | 88 |
| NCT03965858Depressive Disorder, Major · Poland | 2 | Completed | Celon Pharma | Mar 15, 2020 | 88 |
| NCT03852160Depressive Disorder, Treatment-Resistant | 3 | Withdrawn | Johnson & Johnson | Jul 25, 2021 | 0 |
| NCT03434041Depressive Disorder, Treatment-Resistant · United States, China | 3 | Completed | Johnson & Johnson | Apr 13, 2021 | 252 |
| NCT03407872Healthy Volunteers · Poland | 1 | Completed | Celon Pharma | May 20, 2018 | 63 |
| NCT03298906Healthy · Belgium | 1 | Completed | Johnson & Johnson | Nov 27, 2017 | 16 |
| NCT03185819Depressive Disorder, Major · United States, Belgium, Brazil and more | 2 | Completed | Johnson & Johnson | Mar 31, 2023 | 147 |
| NCT03097133Depressive Disorder, Major · United States, Argentina, Austria and more | 3 | Completed | Johnson & Johnson | Apr 11, 2019 | 230 |
| NCT03039192Depressive Disorder, Major · United States, Bulgaria, Estonia and more | 3 | Completed | Johnson & Johnson | Dec 18, 2018 | 226 |
| NCT02918318Depression · Japan | 2 | Completed | Johnson & Johnson | Aug 19, 2019 | 202 |
| NCT02919579Depressive Disorder, Major · Netherlands | 1 | Completed | Johnson & Johnson | Jun 29, 2018 | 27 |
| NCT02857777Healthy · United States | 1 | Completed | Johnson & Johnson | Jan 27, 2017 | 37 |
| NCT02846519Healthy · United States | 1 | Completed | Johnson & Johnson | May 28, 2016 | 66 |
| NCT02782104Depressive Disorder, Treatment-Resistant · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Dec 30, 2022 | 1,148 |
| NCT02737605Healthy · Germany | 1 | Completed | Johnson & Johnson | Feb 23, 2017 | 62 |
| NCT02682225Substance-Related Disorders · United States | 1 | Completed | Johnson & Johnson | Jan 9, 2017 | 55 |
| NCT02674295Healthy · United States | 1 | Completed | Johnson & Johnson | Aug 2016 | 8 |
| NCT02611505Hepatic Impairment · United States | 1 | Completed | Johnson & Johnson | Feb 27, 2017 | 24 |
| NCT02606084Renal Insufficiency · United States | 1 | Completed | Johnson & Johnson | Feb 2, 2018 | 32 |
| NCT02497287Depressive Disorder, Treatment-Resistant · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Oct 28, 2017 | 802 |
| NCT02493868Depressive Disorder, Treatment-Resistant · United States, Belgium, Brazil and more | 3 | Completed | Johnson & Johnson | Feb 15, 2018 | 719 |
| NCT02422186Depressive Disorder, Treatment-Resistant · United States, Belgium, Brazil and more | 3 | Completed | Johnson & Johnson | Aug 10, 2017 | 139 |
| NCT02418585Depressive Disorder, Treatment-Resistant · United States, Czechia, Germany and more | 3 | Completed | Johnson & Johnson | Jun 1, 2017 | 236 |
| NCT02417064Depressive Disorder, Treatment-Resistant · United States, Belgium, Brazil and more | 3 | Completed | Johnson & Johnson | Feb 20, 2018 | 346 |
| NCT02345148Healthy · Belgium | 1 | Completed | Johnson & Johnson | Jan 2015 | 16 |
| NCT02343289Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2015 | 18 |
| NCT02228239Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Dec 2014 | 26 |
| NCT02133001Depressive Disorder, Major · United States | 2 | Completed | Johnson & Johnson | Feb 1, 2016 | 68 |
| NCT02129088Healthy · Belgium | 1 | Completed | Johnson & Johnson | May 2014 | 34 |
| NCT02094378Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Aug 2014 | 24 |
| NCT02060929Healthy · Belgium | 1 | Completed | Johnson & Johnson | Jan 2014 | 14 |
| NCT01998958Depressive Disorder, Treatment-Resistant · United States, Belgium, Japan | 2 | Completed | Johnson & Johnson | Jul 21, 2015 | 108 |
| NCT01980303Healthy Volunteers · United States | 1 | Completed | Johnson & Johnson | Jan 2014 | 29 |
| NCT01780259Healthy · Belgium | 1 | Completed | Johnson & Johnson | May 2013 | 58 |
| NCT01640080Depressive Disorder, Major · Belgium, Germany, Poland | 2 | Completed | Johnson & Johnson | Jun 3, 2013 | 30 |
How it is read
Names in the registry
- “Esketamine”, 30 entries
- “Esketamine 84 mg”, 8 entries
- “Esketamine 56 mg”, 7 entries
- “AM-101”, 5 entries
- “Esketamine 28 mg”, 3 entries
Conditions, from the studies’ own filings
- Depressive Disorder, Treatment-Resistant, 12 studies
- Depressive Disorder, Major, 10 studies
- Tinnitus, 6 studies
- Depression, 3 studies
- Substance-Related Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.